Quarterly ResultMay 14, 2026, 04:24 PM
RenovoRx Q1 Revenue Jumps 186% to $563K; Net Loss Widens
AI Summary
RenovoRx reported a significant increase in Q1 2026 revenue, reaching $563,000, up 186% year-over-year, driven by accelerated commercial rollout of RenovoCath. The company expanded its active commercial cancer centers to 16 and expects to close enrollment for its Phase III TIGeR-PaC trial by the end of June 2026. Despite revenue growth, net loss widened to $3.5 million, and cash used in operations increased, though the company believes current cash is sufficient for at least the next 12 months.
Key Highlights
- Q1 2026 revenue increased 186% year-over-year to $563,000.
- Net loss for Q1 2026 widened to $3.5 million from $2.4 million in Q1 2025.
- Cash and cash equivalents totaled $12.4 million as of March 31, 2026.
- Active commercial cancer centers grew to 16 as of May 6, 2026.
- Phase III TIGeR-PaC trial enrolled 106 of 114 required patients (93%).
- Enrollment for TIGeR-PaC trial expected to close by end of June 2026.
- Company targets 36 active commercial cancer centers by year-end 2026.
Price Impact
More from RNXT